 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DESIPRAMINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DESIPRAMINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DESIPRAMINE increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"desipramine"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: DESIPRAMINE: boxed_warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, [0m
[31madolescents, and young adults in short-term studies of major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Anyone considering the use of desipramine hydrochloride tablets or any other [0m
[31mantidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants [0m
[31mcompared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction in risk with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. Depression and certain other psychiatric disorders are [0m
[31mthemselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical [0m
[31mworsening, suicidality, or unusual changes in behavior. DESIPRAMINE: boxed_warning: Families and caregivers should be advised of the need for close observation and communication with the prescriber. [0m
[31mDesipramine hydrochloride is not approved for use in pediatric patients [0m[1;31m([0m[31m See WARNINGS: Clinical Worsening and Suicide Risk , PRECAUTIONS: Information for Patients , and PRECAUTIONS: Pediatric Use .  [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: warnings: Screening Patients for Bipolar Disorder: A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed [0m[1;31m([0m[31mthough not [0m
[31mestablished in controlled trials[0m[1;31m)[0m[31m that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar [0m
[31mdisorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be[0m
[31madequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and [0m
[31mdepression. It should be noted that desipramine hydrochloride is not approved for use in treating bipolar depression. DESIPRAMINE: warnings: Serotonin Syndrome: The development of a potentially [0m
[31mlife-threatening serotonin syndrome has been reported with serotonin norepinephrine reuptake inhibitors [0m[1;31m([0m[31mSNRIs[0m[1;31m)[0m[31m and SSRIs, including desipramine hydrochloride, alone but particularly with concomitant [0m
[31muse of other serotonergic drugs [0m[1;31m([0m[31mincluding triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort[0m[1;31m)[0m[31m and with drugs that impair metabolism of [0m
[31mserotonin [0m[1;31m([0m[31min particular, MAOIs both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue[0m[1;31m)[0m[31m. Serotonin syndrome symptoms may include mental [0m
[31mstatus changes [0m[1;31m([0m[31me.g., agitation, hallucinations, delirium, and coma[0m[1;31m)[0m[31m, autonomic instability [0m[1;31m([0m[31me.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia[0m[1;31m)[0m[31m, neuromuscular [0m
[31mchanges [0m[1;31m([0m[31me.g. DESIPRAMINE: warnings: tremor, rigidity, myoclonus, hyperreflexia, incoordination[0m[1;31m)[0m[31m, seizures, and/or gastrointestinal symptoms [0m[1;31m([0m[31me.g., nausea, vomiting, diarrhea[0m[1;31m)[0m[31m. Patients should be [0m
[31mmonitored for the emergence of serotonin syndrome. The concomitant use of desipramine hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Desipramine hydrochloride [0m
[31mshould also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of [0m
[31madministration involved intravenous administration in the dose range of [0m[1;31m1[0m[31m mg/kg to [0m[1;31m8[0m[31m mg/kg. No reports involved the administration of methylene blue by other routes [0m[1;31m([0m[31msuch as oral tablets or local [0m
[31mtissue injection[0m[1;31m)[0m[31m or at lower doses. DESIPRAMINE: warnings: There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a [0m
[31mpatient taking desipramine hydrochloride. Desipramine hydrochloride should be discontinued before initiating treatment with the MAOI [0m[1;31m([0m[31m see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. If [0m
[31mconcomitant use of desipramine hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is [0m
[31mclinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome particularly during treatment initiation and dose increases. Treatment with desipramine [0m
[31mhydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. DESIPRAMINE: warnings: [0m
[31mAngle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including desipramine hydrochloride may trigger an angle closure attack in a patient with [0m
[31manatomically narrow angles who does not have a patent iridectomy. General Extreme caution should be used when this drug is given in the following situations: In patients with cardiovascular disease, [0m
[31mbecause of the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial infarction. In patients who have a family history of sudden death, cardiac dysrhythmias, or [0m
[31mcardiac conduction disturbances. In patients with a history of urinary retention or glaucoma, because of the anticholinergic properties of the drug. In patients with thyroid disease or those taking [0m
[31mthyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. In patients with a history of seizure disorder, because this drug has been shown to lower the seizure [0m
[31mthreshold. DESIPRAMINE: warnings: Seizures precede cardiac dysrhythmias and death in some patients. This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting [0m
[31mcompounds. The patient should be cautioned that this drug may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating[0m
[31mmachinery. In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage. Pregnancy There is a [0m
[31mpregnancy exposure registry that monitors pregnancy outcomes in woman exposed to antidepressants, including desipramine hydrochloride tablets during pregnancy. Healthcare providers are encouraged to [0m
[31mregister patients by calling the National Pregnancy Registry for Antidepressants at [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m-[0m[1;31m405[0m[31m-[0m[1;31m6185[0m[31m or visiting online at [0m[4;31mhttp://womensmentalhealth.[0m[31m DESIPRAMINE: warnings: [0m[31m/[0m[31mclinical-and-research-[0m[31m [0m
[31mprograms/pregnancyregistry/antidepressants Safe use of desipramine hydrochloride during pregnancy and lactation has not been established; therefore, if it is to be given to pregnant patients, nursing [0m
[31mmothers, or women of childbearing potential, the possible benefits must be weighed against the possible hazards to mother and child. Animal reproductive studies have been inconclusive. Geriatric Use [0m
[31mClinical studies of desipramine hydrochloride did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported [0m
[31mclinical experience has not identified differences in responses between the elderly and younger patients. Lower doses are recommended for elderly patients. [0m[1;31m([0m[31m See DOSAGE AND ADMINISTRATION .[0m[1;31m)[0m[31m The ratio[0m
[31mof [0m[1;31m2[0m[31m-hydroxydesipramine to desipramine may be increased in the elderly, most likely due to decreased renal elimination with aging. DESIPRAMINE: warnings: This drug is known to be substantially [0m
[31mexcreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function,[0m
[31mcare should be taken in dose selection, and it may be useful to monitor renal function. Desipramine hydrochloride use in the elderly has been associated with a proneness to falling as well as [0m
[31mconfusional states [0m[1;31m([0m[31mSee ADVERSE REACTIONS .         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: precautions: PRECAUTIONS Information for Patients Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and [0m
[31mrisks associated with treatment with desipramine hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about [0m[31m"Antidepressant Medicines, Depression and other Serious [0m
[31mMental illnesses, and Suicidal Thoughts or Actions"[0m[31m is available for desipramine hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to [0m
[31mread the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any [0m
[31mquestions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if [0m
[31mthese occur while taking desipramine hydrochloride. DESIPRAMINE: precautions: Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should be encouraged to be alert to [0m
[31mthe emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, mania, other unusual changes in [0m
[31mbehavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be [0m
[31madvised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, [0m
[31mespecially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and [0m
[31mbehavior and indicate a need for very close monitoring and possibly changes in the medication. DESIPRAMINE: precautions: Patients should be advised that taking desipramine hydrochloride can cause mild[0m
[31mpupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when [0m
[31mdiagnosed, can be treated definitively with iridectomy. Open- angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible[0m
[31mto angle closure, and have a prophylactic procedure [0m[1;31m([0m[31me.g., iridectomy[0m[1;31m)[0m[31m, if they are susceptible. Pediatric Use Safety and effectiveness in the pediatric population have not been established [0m[1;31m([0m[31m see BOX [0m
[31mWARNING and WARNINGS-Clinical Worsening and Suicide Risk [0m[1;31m)[0m[31m. Therefore, desipramine hydrochloride is not recommended for use in children. DESIPRAMINE: precautions: Anyone considering the use of [0m
[31mdesipramine hydrochloride in a child or adolescent must balance the potential risks with the clinical need [0m[1;31m([0m[31msee also ADVERSE REACTIONS- Cardiovascular [0m[1;31m)[0m[31m. General It is important that this drug be [0m
[31mdispensed in the least possible quantities to depressed outpatients, since suicide has been accomplished with this class of drug [0m[1;31m([0m[31m see WARNINGS-Clinical Worsening and Suicide Risk [0m[1;31m)[0m[31m. Ordinary prudence[0m
[31mrequires that children not have access to this drug or to potent drugs of any kind; if possible, this drug should be dispensed in containers with child-resistant safety closures. Storage of this drug [0m
[31min the home must be supervised responsibly. If serious adverse effects occur, dosage should be reduced or treatment should be altered. Desipramine hydrochloride therapy in patients with [0m
[31mmanic-depressive illness may induce a hypomanic state after the depressive phase terminates. The drug may cause exacerbation of psychosis in schizophrenic patients. Both elevation and lowering of [0m
[31mblood sugar levels have been reported. DESIPRAMINE: precautions: Leukocyte and differential counts should be performed in any patient who develops fever and sore throat during therapy; the drug should[0m
[31mbe discontinued if there is evidence of pathologic neutrophil depression. Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited. Thus, if such treatment is [0m
[31messential, the possibility of increased risk relative to benefits should be considered. This drug should be discontinued as soon as possible prior to elective surgery because of possible [0m
[31mcardiovascular effects. Hypertensive episodes have been observed during surgery in patients taking desipramine hydrochloride.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: warnings: WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m, both adult and pediatric, may experience worsening of their depression [0m
[31mand/or the emergence of suicidal ideation and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until [0m
[31msignificant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a [0m
[31mlong- standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. [0m
[31mDESIPRAMINE: warnings: Pooled analyses of short-term placebo-controlled trials of antidepressant drugs [0m[1;31m([0m[31mselective serotonin reuptake inhibitors [0m[1;31m[[0m[31mSSRIs[0m[1;31m][0m[31m and others[0m[1;31m)[0m[31m showed that these drugs increase the[0m
[31mrisk of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, adolescents, and young adults [0m[1;31m([0m[31mages [0m[1;31m18[0m[31m-[0m[1;31m24[0m[1;31m)[0m[31m with major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Short-term studies [0m
[31mdid not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m [0m
[31mand older. The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder [0m[1;31m([0m[31mOCD[0m[1;31m)[0m[31m, or other psychiatric disorders included a total of [0m[1;31m24[0m[31m short-term [0m
[31mtrials of [0m[1;31m9[0m[31m antidepressant drugs in over [0m[1;31m4400[0m[31m patients. DESIPRAMINE: warnings: The pooled analyses of placebo- controlled trials in adults with MDD or other psychiatric disorders included a total of [0m
[1;31m295[0m[31m short-term trials [0m[1;31m([0m[31mmedian duration of [0m[1;31m2[0m[31m months[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m antidepressant drugs in over [0m[1;31m77[0m[31m,[0m[1;31m000[0m[31m patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an [0m
[31mincrease in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk [0m
[31mdifferences [0m[1;31m([0m[31mdrug vs placebo[0m[1;31m)[0m[31m, however, were relatively stable within age strata and across indications. These risk differences [0m[1;31m([0m[31mdrug-placebo difference in the number of cases of suicidality per [0m[1;31m1000[0m[31m [0m
[31mpatients treated[0m[1;31m)[0m[31m are provided in Table [0m[1;31m1[0m[31m . DESIPRAMINE: warnings: Table [0m[1;31m1[0m[31m Age Range Drug-Placebo Difference in Number of Cases of Suicidality per [0m[1;31m1000[0m[31m Patients Treated Increases Compared to Placebo [0m
[31m<[0m[1;31m18[0m[31m [0m[1;31m14[0m[31m additional cases [0m[1;31m18[0m[31m-[0m[1;31m24[0m[31m [0m[1;31m5[0m[31m additional cases Decreases Compared to Placebo [0m[1;31m25[0m[31m-[0m[1;31m64[0m[31m [0m[1;31m1[0m[31m fewer case ≥[0m[1;31m65[0m[31m [0m[1;31m6[0m[31m fewer cases No suicides occurred in any of the pediatric trials. There were suicides in the [0m
[31madult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several [0m
[31mmonths. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. DESIPRAMINE:[0m
[31mwarnings: All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in [0m
[31mbehavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, [0m
[31minsomnia, irritability, hostility, aggressiveness, impulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, and mania, have been reported in adult and pediatric patients being treated with [0m
[31mantidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the [0m
[31mworsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. DESIPRAMINE: warnings:[0m
[31mConsideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent[0m
[31msuicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting [0m
[31msymptoms. Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the [0m
[31mneed to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such [0m
[31msymptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for desipramine hydrochloride should be written for the [0m
[31msmallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: contraindications: CONTRAINDICATIONS The use of MAOIs intended to treat psychiatric disorders with desipramine hydrochloride or within [0m[1;31m14[0m[31m days of stopping treatment with [0m
[31mdesipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of desipramine hydrochloride within [0m[1;31m14[0m[31m days of stopping an MAOI intended to treat psychiatric [0m
[31mdisorders is also contraindicated [0m[1;31m([0m[31m see WARNINGS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Starting desipramine hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous [0m
[31mmethylene blue is also contraindicated because of an increased risk of serotonin syndrome [0m[1;31m([0m[31msee WARNINGS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Desipramine hydrochloride is contraindicated in the acute [0m
[31mrecovery period following myocardial infarction. It should not be used in those who have shown prior hypersensitivity to the drug. DESIPRAMINE: contraindications: Cross-sensitivity between this and [0m
[31mother dibenzazepines is a possibility.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"desipramine"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does DESIPRAMINE increase or decrease the risk of [0m
[31mrenal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DESIPRAMINE increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DESIPRAMINE increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"desipramine"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: DESIPRAMINE: boxed_warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, [0m
[31madolescents, and young adults in short-term studies of major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Anyone considering the use of desipramine hydrochloride tablets or any other [0m
[31mantidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants [0m
[31mcompared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction in risk with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. Depression and certain other psychiatric disorders are [0m
[31mthemselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical [0m
[31mworsening, suicidality, or unusual changes in behavior. DESIPRAMINE: boxed_warning: Families and caregivers should be advised of the need for close observation and communication with the prescriber. [0m
[31mDesipramine hydrochloride is not approved for use in pediatric patients [0m[1;31m([0m[31m See WARNINGS: Clinical Worsening and Suicide Risk , PRECAUTIONS: Information for Patients , and PRECAUTIONS: Pediatric Use .  [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: warnings: Screening Patients for Bipolar Disorder: A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed [0m[1;31m([0m[31mthough not [0m
[31mestablished in controlled trials[0m[1;31m)[0m[31m that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar [0m
[31mdisorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be[0m
[31madequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and [0m
[31mdepression. It should be noted that desipramine hydrochloride is not approved for use in treating bipolar depression. DESIPRAMINE: warnings: Serotonin Syndrome: The development of a potentially [0m
[31mlife-threatening serotonin syndrome has been reported with serotonin norepinephrine reuptake inhibitors [0m[1;31m([0m[31mSNRIs[0m[1;31m)[0m[31m and SSRIs, including desipramine hydrochloride, alone but particularly with concomitant [0m
[31muse of other serotonergic drugs [0m[1;31m([0m[31mincluding triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort[0m[1;31m)[0m[31m and with drugs that impair metabolism of [0m
[31mserotonin [0m[1;31m([0m[31min particular, MAOIs both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue[0m[1;31m)[0m[31m. Serotonin syndrome symptoms may include mental [0m
[31mstatus changes [0m[1;31m([0m[31me.g., agitation, hallucinations, delirium, and coma[0m[1;31m)[0m[31m, autonomic instability [0m[1;31m([0m[31me.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia[0m[1;31m)[0m[31m, neuromuscular [0m
[31mchanges [0m[1;31m([0m[31me.g. DESIPRAMINE: warnings: tremor, rigidity, myoclonus, hyperreflexia, incoordination[0m[1;31m)[0m[31m, seizures, and/or gastrointestinal symptoms [0m[1;31m([0m[31me.g., nausea, vomiting, diarrhea[0m[1;31m)[0m[31m. Patients should be [0m
[31mmonitored for the emergence of serotonin syndrome. The concomitant use of desipramine hydrochloride with MAOIs intended to treat psychiatric disorders is contraindicated. Desipramine hydrochloride [0m
[31mshould also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of [0m
[31madministration involved intravenous administration in the dose range of [0m[1;31m1[0m[31m mg/kg to [0m[1;31m8[0m[31m mg/kg. No reports involved the administration of methylene blue by other routes [0m[1;31m([0m[31msuch as oral tablets or local [0m
[31mtissue injection[0m[1;31m)[0m[31m or at lower doses. DESIPRAMINE: warnings: There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a [0m
[31mpatient taking desipramine hydrochloride. Desipramine hydrochloride should be discontinued before initiating treatment with the MAOI [0m[1;31m([0m[31m see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. If [0m
[31mconcomitant use of desipramine hydrochloride with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is [0m
[31mclinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome particularly during treatment initiation and dose increases. Treatment with desipramine [0m
[31mhydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. DESIPRAMINE: warnings: [0m
[31mAngle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including desipramine hydrochloride may trigger an angle closure attack in a patient with [0m
[31manatomically narrow angles who does not have a patent iridectomy. General Extreme caution should be used when this drug is given in the following situations: In patients with cardiovascular disease, [0m
[31mbecause of the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial infarction. In patients who have a family history of sudden death, cardiac dysrhythmias, or [0m
[31mcardiac conduction disturbances. In patients with a history of urinary retention or glaucoma, because of the anticholinergic properties of the drug. In patients with thyroid disease or those taking [0m
[31mthyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. In patients with a history of seizure disorder, because this drug has been shown to lower the seizure [0m
[31mthreshold. DESIPRAMINE: warnings: Seizures precede cardiac dysrhythmias and death in some patients. This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting [0m
[31mcompounds. The patient should be cautioned that this drug may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating[0m
[31mmachinery. In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage. Pregnancy There is a [0m
[31mpregnancy exposure registry that monitors pregnancy outcomes in woman exposed to antidepressants, including desipramine hydrochloride tablets during pregnancy. Healthcare providers are encouraged to [0m
[31mregister patients by calling the National Pregnancy Registry for Antidepressants at [0m[1;31m1[0m[31m-[0m[1;31m844[0m[31m-[0m[1;31m405[0m[31m-[0m[1;31m6185[0m[31m or visiting online at [0m[4;31mhttp://womensmentalhealth.[0m[31m DESIPRAMINE: warnings: [0m[31m/[0m[31mclinical-and-research-[0m[31m [0m
[31mprograms/pregnancyregistry/antidepressants Safe use of desipramine hydrochloride during pregnancy and lactation has not been established; therefore, if it is to be given to pregnant patients, nursing [0m
[31mmothers, or women of childbearing potential, the possible benefits must be weighed against the possible hazards to mother and child. Animal reproductive studies have been inconclusive. Geriatric Use [0m
[31mClinical studies of desipramine hydrochloride did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported [0m
[31mclinical experience has not identified differences in responses between the elderly and younger patients. Lower doses are recommended for elderly patients. [0m[1;31m([0m[31m See DOSAGE AND ADMINISTRATION .[0m[1;31m)[0m[31m The ratio[0m
[31mof [0m[1;31m2[0m[31m-hydroxydesipramine to desipramine may be increased in the elderly, most likely due to decreased renal elimination with aging. DESIPRAMINE: warnings: This drug is known to be substantially [0m
[31mexcreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function,[0m
[31mcare should be taken in dose selection, and it may be useful to monitor renal function. Desipramine hydrochloride use in the elderly has been associated with a proneness to falling as well as [0m
[31mconfusional states [0m[1;31m([0m[31mSee ADVERSE REACTIONS .         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: precautions: PRECAUTIONS Information for Patients Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and [0m
[31mrisks associated with treatment with desipramine hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about [0m[31m"Antidepressant Medicines, Depression and other Serious [0m
[31mMental illnesses, and Suicidal Thoughts or Actions"[0m[31m is available for desipramine hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to [0m
[31mread the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any [0m
[31mquestions they may have. The complete text of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if [0m
[31mthese occur while taking desipramine hydrochloride. DESIPRAMINE: precautions: Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should be encouraged to be alert to [0m
[31mthe emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, mania, other unusual changes in [0m
[31mbehavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be [0m
[31madvised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, [0m
[31mespecially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and [0m
[31mbehavior and indicate a need for very close monitoring and possibly changes in the medication. DESIPRAMINE: precautions: Patients should be advised that taking desipramine hydrochloride can cause mild[0m
[31mpupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when [0m
[31mdiagnosed, can be treated definitively with iridectomy. Open- angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible[0m
[31mto angle closure, and have a prophylactic procedure [0m[1;31m([0m[31me.g., iridectomy[0m[1;31m)[0m[31m, if they are susceptible. Pediatric Use Safety and effectiveness in the pediatric population have not been established [0m[1;31m([0m[31m see BOX [0m
[31mWARNING and WARNINGS-Clinical Worsening and Suicide Risk [0m[1;31m)[0m[31m. Therefore, desipramine hydrochloride is not recommended for use in children. DESIPRAMINE: precautions: Anyone considering the use of [0m
[31mdesipramine hydrochloride in a child or adolescent must balance the potential risks with the clinical need [0m[1;31m([0m[31msee also ADVERSE REACTIONS- Cardiovascular [0m[1;31m)[0m[31m. General It is important that this drug be [0m
[31mdispensed in the least possible quantities to depressed outpatients, since suicide has been accomplished with this class of drug [0m[1;31m([0m[31m see WARNINGS-Clinical Worsening and Suicide Risk [0m[1;31m)[0m[31m. Ordinary prudence[0m
[31mrequires that children not have access to this drug or to potent drugs of any kind; if possible, this drug should be dispensed in containers with child-resistant safety closures. Storage of this drug [0m
[31min the home must be supervised responsibly. If serious adverse effects occur, dosage should be reduced or treatment should be altered. Desipramine hydrochloride therapy in patients with [0m
[31mmanic-depressive illness may induce a hypomanic state after the depressive phase terminates. The drug may cause exacerbation of psychosis in schizophrenic patients. Both elevation and lowering of [0m
[31mblood sugar levels have been reported. DESIPRAMINE: precautions: Leukocyte and differential counts should be performed in any patient who develops fever and sore throat during therapy; the drug should[0m
[31mbe discontinued if there is evidence of pathologic neutrophil depression. Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited. Thus, if such treatment is [0m
[31messential, the possibility of increased risk relative to benefits should be considered. This drug should be discontinued as soon as possible prior to elective surgery because of possible [0m
[31mcardiovascular effects. Hypertensive episodes have been observed during surgery in patients taking desipramine hydrochloride.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: warnings: WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m, both adult and pediatric, may experience worsening of their depression [0m
[31mand/or the emergence of suicidal ideation and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until [0m
[31msignificant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a [0m
[31mlong- standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. [0m
[31mDESIPRAMINE: warnings: Pooled analyses of short-term placebo-controlled trials of antidepressant drugs [0m[1;31m([0m[31mselective serotonin reuptake inhibitors [0m[1;31m[[0m[31mSSRIs[0m[1;31m][0m[31m and others[0m[1;31m)[0m[31m showed that these drugs increase the[0m
[31mrisk of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, adolescents, and young adults [0m[1;31m([0m[31mages [0m[1;31m18[0m[31m-[0m[1;31m24[0m[1;31m)[0m[31m with major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Short-term studies [0m
[31mdid not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m [0m
[31mand older. The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder [0m[1;31m([0m[31mOCD[0m[1;31m)[0m[31m, or other psychiatric disorders included a total of [0m[1;31m24[0m[31m short-term [0m
[31mtrials of [0m[1;31m9[0m[31m antidepressant drugs in over [0m[1;31m4400[0m[31m patients. DESIPRAMINE: warnings: The pooled analyses of placebo- controlled trials in adults with MDD or other psychiatric disorders included a total of [0m
[1;31m295[0m[31m short-term trials [0m[1;31m([0m[31mmedian duration of [0m[1;31m2[0m[31m months[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m antidepressant drugs in over [0m[1;31m77[0m[31m,[0m[1;31m000[0m[31m patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an [0m
[31mincrease in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk [0m
[31mdifferences [0m[1;31m([0m[31mdrug vs placebo[0m[1;31m)[0m[31m, however, were relatively stable within age strata and across indications. These risk differences [0m[1;31m([0m[31mdrug-placebo difference in the number of cases of suicidality per [0m[1;31m1000[0m[31m [0m
[31mpatients treated[0m[1;31m)[0m[31m are provided in Table [0m[1;31m1[0m[31m . DESIPRAMINE: warnings: Table [0m[1;31m1[0m[31m Age Range Drug-Placebo Difference in Number of Cases of Suicidality per [0m[1;31m1000[0m[31m Patients Treated Increases Compared to Placebo [0m
[31m<[0m[1;31m18[0m[31m [0m[1;31m14[0m[31m additional cases [0m[1;31m18[0m[31m-[0m[1;31m24[0m[31m [0m[1;31m5[0m[31m additional cases Decreases Compared to Placebo [0m[1;31m25[0m[31m-[0m[1;31m64[0m[31m [0m[1;31m1[0m[31m fewer case ≥[0m[1;31m65[0m[31m [0m[1;31m6[0m[31m fewer cases No suicides occurred in any of the pediatric trials. There were suicides in the [0m
[31madult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several [0m
[31mmonths. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. DESIPRAMINE:[0m
[31mwarnings: All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in [0m
[31mbehavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, [0m
[31minsomnia, irritability, hostility, aggressiveness, impulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, and mania, have been reported in adult and pediatric patients being treated with [0m
[31mantidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the [0m
[31mworsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. DESIPRAMINE: warnings:[0m
[31mConsideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent[0m
[31msuicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting [0m
[31msymptoms. Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the [0m
[31mneed to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such [0m
[31msymptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for desipramine hydrochloride should be written for the [0m
[31msmallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m


[31mCONTENT: DESIPRAMINE: contraindications: CONTRAINDICATIONS The use of MAOIs intended to treat psychiatric disorders with desipramine hydrochloride or within [0m[1;31m14[0m[31m days of stopping treatment with [0m
[31mdesipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of desipramine hydrochloride within [0m[1;31m14[0m[31m days of stopping an MAOI intended to treat psychiatric [0m
[31mdisorders is also contraindicated [0m[1;31m([0m[31m see WARNINGS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Starting desipramine hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous [0m
[31mmethylene blue is also contraindicated because of an increased risk of serotonin syndrome [0m[1;31m([0m[31msee WARNINGS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Desipramine hydrochloride is contraindicated in the acute [0m
[31mrecovery period following myocardial infarction. It should not be used in those who have shown prior hypersensitivity to the drug. DESIPRAMINE: contraindications: Cross-sensitivity between this and [0m
[31mother dibenzazepines is a possibility.         [0m
[31mSOUR[0m[1;31mCE:DE[0m[31mSIPRAMINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Desipramine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, while it does [0m
[32mnot specifically state that desipramine increases the risk of renal failure, it suggests that caution should be taken in dose selection for patients with decreased renal function, and it may be useful[0m
[32mto monitor renal function in such patients.[0m

[32mSOURCE: DESIPRAMINE label[0m
[32mEXTRACT_START_END: This drug is known to be [0m[32m...[0m[32m monitor renal function.[0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Desipramine is known to be substantially excreted by the kidney,[0m
[34mand the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, while it does not specifically state that desipramine increases the risk of renal [0m
[34mfailure, it suggests that caution should be taken in dose selection for patients with decreased renal function, and it may be useful to monitor renal function in such patients.[0m

[34mSOURCE: DESIPRAMINE label[0m
[34mEXTRACT_START_END: This drug is known to be [0m[34m...[0m[34m monitor renal function.[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if DESIPRAMINE increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded by indicating that DESIPRAMINE is substantially excreted by the kidney and that the risk of toxic reactions may be greater in patients with impaired renal function. It [0m
[32msuggests caution in dose selection for patients with decreased renal function and that it may be useful to monitor renal function in such patients."[0m[32m,[0m
[32m      [0m[32m"Although this does not directly state that DESIPRAMINE increases the risk of renal failure, it implies that there is a potential for increased risk in patients with existing renal impairment [0m
[32mdue to the possibility of toxic reactions."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DESIPRAMINE may increase the risk of toxic reactions in patients with impaired renal function, suggesting a potential for increased risk of renal failure in this patient group. However,[0m
[32mthe FDA label does not explicitly state that DESIPRAMINE increases the risk of renal failure. It is recommended to use caution in dose selection and to monitor renal function in patients with [0m
[32mdecreased renal function."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DESIPRAMINE increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if DESIPRAMINE increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded by indicating that DESIPRAMINE is substantially excreted by the kidney and that the risk of toxic reactions may be greater in patients with impaired renal function. It [0m
[34msuggests caution in dose selection for patients with decreased renal function and that it may be useful to monitor renal function in such patients."[0m[34m,[0m
[34m      [0m[34m"Although this does not directly state that DESIPRAMINE increases the risk of renal failure, it implies that there is a potential for increased risk in patients with existing renal impairment [0m
[34mdue to the possibility of toxic reactions."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DESIPRAMINE may increase the risk of toxic reactions in patients with impaired renal function, suggesting a potential for increased risk of renal failure in this patient group. However,[0m
[34mthe FDA label does not explicitly state that DESIPRAMINE increases the risk of renal failure. It is recommended to use caution in dose selection and to monitor renal function in patients with [0m
[34mdecreased renal function."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DESIPRAMINE increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if DESIPRAMINE increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded by indicating that DESIPRAMINE is substantially excreted by the kidney and that the risk of toxic reactions may be greater in patients with impaired renal function. It suggests[0m
[31mcaution in dose selection for patients with decreased renal function and that it may be useful to monitor renal function in such patients.[0m
[1;31m3[0m[31m. Although this does not directly state that DESIPRAMINE increases the risk of renal failure, it implies that there is a potential for increased risk in patients with existing renal impairment due to[0m
[31mthe possibility of toxic reactions.[0m
[31m        -----[0m
[31m        Final answer: DESIPRAMINE may increase the risk of toxic reactions in patients with impaired renal function, suggesting a potential for increased risk of renal failure in this patient group. [0m
[31mHowever, the FDA label does not explicitly state that DESIPRAMINE increases the risk of renal failure. It is recommended to use caution in dose selection and to monitor renal function in patients with[0m
[31mdecreased renal function.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally sound. The user has correctly interpreted the information from FDAHandler regarding the excretion of DESIPRAMINE and its potential toxic reactions [0m
[32min patients with impaired renal function. The user has made a logical inference that there may be an increased risk of renal failure in patients with existing renal impairment, which is consistent [0m
[32mwith the caution advised for dose selection and monitoring renal function. The user has also appropriately noted that the FDA label does not explicitly state an increased risk of renal failure, which [0m
[32mis an important distinction. The user has expressed the strength of evidence and the magnitude of the effect appropriately, given the information provided by FDAHandler."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally sound. The user has correctly interpreted the information from FDAHandler regarding the excretion of DESIPRAMINE and its potential toxic reactions [0m
[34min patients with impaired renal function. The user has made a logical inference that there may be an increased risk of renal failure in patients with existing renal impairment, which is consistent [0m
[34mwith the caution advised for dose selection and monitoring renal function. The user has also appropriately noted that the FDA label does not explicitly state an increased risk of renal failure, which [0m
[34mis an important distinction. The user has expressed the strength of evidence and the magnitude of the effect appropriately, given the information provided by FDAHandler."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally sound. The user has correctly interpreted the information from FDAHandler regarding the excretion of DESIPRAMINE and its potential toxic reactions[0m
[31min patients with impaired renal function. The user has made a logical inference that there may be an increased risk of renal failure in patients with existing renal impairment, which is consistent [0m
[31mwith the caution advised for dose selection and monitoring renal function. The user has also appropriately noted that the FDA label does not explicitly state an increased risk of renal failure, which [0m
[31mis an important distinction. The user has expressed the strength of evidence and the magnitude of the effect appropriately, given the information provided by FDAHandler.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-DESIPRAMINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether DESIPRAMINE increases or decreases the risk of renal failure. Based on the information provided by FDAHandler, DESIPRAMINE is known to be substantially excreted by the kidney,[0m
[32mand there may be a greater risk of toxic reactions to this drug in patients with impaired renal function. The FDA label advises caution in dose selection for patients with decreased renal function and[0m
[32msuggests that it may be useful to monitor renal function in such patients. While this information does not explicitly state that DESIPRAMINE increases the risk of renal failure, it implies that there [0m
[32mis a potential for increased risk in patients with existing renal impairment due to the possibility of toxic reactions. Therefore, DESIPRAMINE may increase the risk of toxic reactions in patients with[0m
[32mimpaired renal function, suggesting a potential for increased risk of renal failure in this patient group. However, the FDA label does not explicitly state that DESIPRAMINE increases the risk of renal[0m
[32mfailure. It is recommended to use caution in dose selection and to monitor renal function in patients with decreased renal function.[0m
